Nantahala Capital Management LLC Acquires New Stake in InspireMD, Inc. $NSPR

Nantahala Capital Management LLC bought a new position in InspireMD, Inc. (NYSE:NSPR) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 3,376,484 shares of the company’s stock, valued at approximately $2,363,876. Nantahala Capital Management LLC owned 7.21% of InspireMD as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Renaissance Technologies LLC purchased a new stake in shares of InspireMD during the first quarter valued at $29,000. XTX Topco Ltd purchased a new position in InspireMD in the 4th quarter worth about $30,000. Virtu Financial LLC bought a new stake in InspireMD during the 4th quarter valued at about $31,000. Creative Planning bought a new stake in InspireMD during the 2nd quarter valued at about $44,000. Finally, Legato Capital Management LLC purchased a new stake in InspireMD in the 4th quarter valued at about $48,000. 44.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NSPR has been the topic of a number of research analyst reports. Lake Street Capital set a $4.00 target price on shares of InspireMD in a research note on Monday, May 4th. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, InspireMD has a consensus rating of “Buy” and an average target price of $4.50.

InspireMD Stock Performance

NYSE:NSPR opened at $0.85 on Friday. InspireMD, Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $2.56. The stock has a market capitalization of $39.52 million, a P/E ratio of -1.13 and a beta of 0.81. The company’s 50-day simple moving average is $0.75 and its 200-day simple moving average is $1.14.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.